The global market for enzyme inhibitors was valued at $104.4 billion in
2010 and reached nearly $104.6 billion in 2011. This market is expected to
rise at a compound annual growth rate (CAGR) of 4% and reach nearly $127.4
billion by 2016.
The emerging markets segment for enzyme inhibitors was $25.6 billion in
2010 and $27.2 billion in 2011. This segment is expected to rise at a CAGR of
8.7% and reach nearly $41.3 billion through 2016.
Sales of kinase inhibitors in emerging markets were $8.2 billion in 2010
and $9.3 billion in 2011. This sector is expected to grow at a CAGR of 13% and
reach nearly $17.1 billion by 2016.
SUMMARY FIGURE
GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016
($ MILLIONS)
Source: BCC Research
STUDY GOALS AND OBJECTIVES
The overall goal of this study is to provide a comprehensive understanding of
the current and future characteristics of the global market for enzyme
inhibitors.
This report explores present and future strategies within the market for
enzyme inhibitors, which includes proton pump inhibitors (PPIs), protease
inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins,
aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors,
neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors.
The improvements in the market and the setbacks and needs of the market are
discussed in this report. The comparisons, usage, and advantages and
disadvantages of different types of enzyme inhibitors are also discussed in
this report.
A detailed analysis of the enzyme inhibitors industry structure has been
conducted. Revenues are broken down by region. Sales figures are estimated
for the five-year forecast period of this report, from 2011 to 2016.
Applications for enzyme inhibitors are also discussed in the report, with
emphasis on the usage of the inhibitors in therapeutic categories and various
disease sectors. The report also covers significant patents and their
allotments in each category.
REASONS FOR DOING THE STUDY
Extensive research in the field of enzyme inhibitors has revealed their
target-specific functionality in being able to provide therapeutic treatments
for various chronic diseases. Modern industries have now begun to explore the
advantages of enzyme inhibitors in their productions and processes. This has
led to steady market growth for enzyme inhibitors.
Research and development (R&D) spending, along with increasing competition,
patent expirations and new technologies, is directing this to a new level.
Although, due to patent expirations, the overall revenue for the market has
decreased slightly from 2009 to 2011, new advancements, new product launches
and the changing lifestyle will cause the market to grow in the foreseeable
future. This study looks at almost all the systems affected by these factors.
Acquisition strategies and collaborations by companies are also covered in
this report. This study also discusses the strengths and weaknesses of each
type/technology in light of the new technologies, growing competition and
changing customer needs.
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
This report provides invaluable information to manufacturers and users of
PPIs, protease inhibitors, reverse transcriptase inhibitors, kinase
inhibitors, statins, aromatase inhibitors, PDE5 inhibitors, neuraminidase
inhibitors, and ACE inhibitors. Pharmaceutical and biotechnology companies,
research institutes, and physicians will find this study to be of interest.
SCOPE OF REPORT
The scope of this study encompasses enzyme inhibitors in the pharmaceutical
and biotechnology industry. BCC Research analyzes each market and its
applications, regulatory environment, technology involved, market projections
and market share. Technological issues include the latest trends and
developments. Emerging markets for enzyme inhibitors include countries such
as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New
Zealand.
METHODOLOGY AND INFORMATION SOURCES
BCC conducted a comprehensive literature search, which included technical
newsletters and journals. The data were collected through interviews and
correspondence with technical experts manufacturing enzyme inhibitors.
Projections were based on estimates such as the current number of end users,
potential end users, mergers and acquisitions, and market trends.
Many companies within the industry were surveyed to obtain data for this
study. Included were manufacturers and end users of enzyme inhibitors in
therapeutic categories and various disease sectors industries. The data were
carefully collected from various industry sources. BCC spoke with officials
within the industry and consulted newsletters; company and product literature;
and a host of technical articles, journals, indexes and abstracts. Exhaustive
investigations of databases by key terminology were completed. In addition,
the data were compiled from current financial, trade and government sources.
ANALYST CREDENTIALS
The study has been carried out by a team of professionals in the biotechnology
industry. The project manager for this project is Shalini S. Dewan, who holds
a master's degree in pharmaceutical chemistry and has more than 14 years of
industry experience. Among the research topics she has covered are studies on
compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl
acetic acid. Dewan was awarded a Gold Medal by the prime minister of India
for her work and has worked with top companies in India and in the U.S.
The lead consultant for this project is Dr. Kapil A. Setia, who has a
doctorate in life sciences. She has a number of research publications in her
credit, including her thesis on “Studies on Phenotypic Variation, Clonal
Propagation and Phyto-chemistry of Tinospora cordifolia (Willd.),” which was
given an award of excellence.
Table of Contents
Table of Contents
Global Markets for Enzyme Inhibitors -- Focus on Emerging Markets
Chapter - 1: INTRODUCTION - Complimentary
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
SCOPE OF REPORT
METHODOLOGY AND INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED REPORTS
BCC ON-LINE SERVICES
DISCLAIMER
Chapter - 2: SUMMARY
Table Summary: GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016
Figure Summary: GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016
Chapter - 3: OVERVIEW
DEFINITIONS
STRUCTURE OF ENZYMES
ACTIVATION ENERGY
SPECIFICITY
ENZYME SUBSTRATE INTERACTION
CONDITIONS OF ENZYME ACTION
CLASSIFICATION OF ENZYMES
REAL-LIFE APPLICATIONS OF ENZYMES
NEED FOR ENZYMES IN HUMAN BODY
WHAT ARE ENZYME INHIBITORS
WHY ENZYME INHIBITION
USE OF ENZYME INHIBITORS
MECHANISM OF ENZYME INHIBITION
TYPES OF ENZYME INHIBITORS
CLASSIFICATION OF ENZYME INHIBITORS
Chapter - 4: REGULATORY ASPECTS
Table 5: NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-2011
Table 6: NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS
Table 7: SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011
Chapter - 5: MARKET LEADERS AND THEIR PRODUCTS FOR ENZYME INHIBITORS
Table 8: LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS
Table 9: LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS
Table 10: LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS
Table 11: LEADING MANUFACTURERS/SUPPLIERS OF STATINS
Table 12: LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS
Table 13: LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE
INHIBITORS
Table 14: LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS
Table 15: LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS
Table 16: LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS
Chapter - 6: NEW DEVELOPMENTS
NEW DRUGS IN CLINICAL TRIALS
Table 27: NEW ENZYME INHIBITORS IN CLINICAL TRIALS
Chapter - 7: GLOBAL MARKETS
MARKET ANALYSIS
MARKET SHARES
MARKET BY APPLICATIONS
Table 28: GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016
Figure 1: GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016
Chapter - 8: EMERGING MARKETS
MARKET ANALYSIS
MARKET SHARES OF INDUSTRY LEADERS IN EMERGING MARKETS
MARKET BY APPLICATIONS
Table 56: EMERGING MARKETS FOR ENZYME INHIBITORS, THROUGH 2016
Figure 29: EMERGING MARKET FOR ENZYME INHIBITORS, 2009-2016
Chapter - 9: PATENT ANALYSIS
PATENTS BY YEAR
PATENTS BY TYPE
PATENTS BY COMPANY
PATENTS BY COUNTRY
PATENTS BY ASSIGNEE
Table 83: NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008-2012
Figure 56: NUMBER OF PATENTS BY YEAR, 2008-2012
Figure 57: NUMBER OF PATENTS BY YEAR, 2008-2012
Chapter - 10: CURRENT SITUATION
MARKET CONDITIONS
TRENDS AND ISSUES IN ENZYME INHIBITORS MARKET
Chapter - 11: COMPANY PROFILES
ABBOTT LABORATORIES
AMGEN INC.
ASTRAZENECA PLC
AUROBINDO PHARMA
BAYER HEALTHCARE PHARMACEUTICALS
BOEHRINGER INGELHEIM GMBH
BRISTOL-MYERS SQUIBB
CIPLA LTD.
DR. REDDY'S LABORATORIES LTD.
EISAI INC.
ELI LILLY & CO.
ENDO PHARMACEUTICALS
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
GLENMARK GENERICS LTD.
HETERO DRUGS LTD.
HOFFMAN-LA ROCHE LTD.
INCYTE CORP.
JOHNSON & JOHNSON
LUPIN PHARMACEUTICALS INC.
MERCK & CO. INC.
MERCK SERONO SA
MYLAN LABORATORIES INC.
MYLAN LABORATORIES LTD.
NOVARTIS AG
OSI PHARMACEUTICALS LLC
PAR PHARMACEUTICAL COMPANIES INC.
PFIZER INC.
RANBAXY LABORATORIES LTD.
ROXANE LABORATORIES LTD.
SANDOZ
SANOFI-AVENTIS
SANTARUS INC.
SUN PHARMACEUTICALS
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VERTEX PHARMACEUTICALS
VIIV HEALTHCARE
WATSON PHARMACEUTICALS INC.
Chapter - 12: APPENDIX - ABBREVIATIONS
List of Tables
Summary Table: GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016
Table 1: CLASSIFICATION OF ENZYME INHIBITORS
Table 2: HISTORY OF DEVELOPMENT OF STATINS
Table 3: HISTORY OF DISCOVERY OF PROTEASE INHIBITORS
Table 4: DEVELOPMENT OF ACE INHIBITORS
Table 5: NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-2011
Table 6: NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS
Table 7: SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011
Table 8: LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS
Table 9: LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS
Table 10: LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS
Table 11: LEADING MANUFACTURERS/SUPPLIERS OF STATINS
Table 12: LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS
Table 13: LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE
INHIBITORS
Table 14: LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS
Table 15: LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS
Table 16: LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS
Table 17: CLINICAL TRIALS ENZYME INHIBITORS
Table 18: CLINICAL TRIALS OF STATINS
Table 19: CLINICAL TRIALS FOR AROMATASE INHIBITORS
Table 20: CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE INHIBITORS
Table 21: CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS
Table 22: CLINICAL TRIALS FOR PDE5 INHIBITORS
Table 23: CLINICAL TRIALS FOR PDE4 INHIBITORS
Table 24: CLINICAL TRIALS FOR PROTEASE INHIBITORS
Table 25: CLINICAL TRIALS FOR ACE INHIBITORS
Table 26: CLINICAL TRIALS FOR PROTON PUMP INHIBITORS
Table 27: NEW ENZYME INHIBITORS IN CLINICAL TRIALS
Table 28: GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016
Table 29: GLOBAL MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016
Table 30: GLOBAL MARKET FOR PROTEASE INHIBITORS, THROUGH 2016
Table 31: GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016
Table 32: GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016
Table 33: GLOBAL MARKET FOR STATINS, THROUGH 2016
Table 34: GLOBAL MARKET FOR AROMATASE INHIBITORS, THROUGH 2016
Table 35: GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH 2016
Table 36: GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016
Table 37: GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2016
Table 38: PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010
Table 39: PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010
Table 40: REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010
Table 41: KINASE INHIBITOR MARKET SHARES BY REGION, 2010
Table 42: STATINS INHIBITOR MARKET SHARES BY REGION, 2010
Table 43: AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010
Table 44: PDE5 INHIBITOR MARKET SHARES BY REGION, 2010
Table 45: NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010
Table 46: ACE INHIBITOR MARKET SHARES BY REGION, 2010
Table 47: GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/
DISEASE SECTORS, THROUGH 2016
Table 48: GLOBAL MARKET FOR ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,
THROUGH 2016
Table 49: GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,
THROUGH 2016
Table 50: GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016
Table 51: GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016
Table 52: GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH
2016
Table 53: GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,
THROUGH 2016
Table 54: GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016
Table 55: GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION, 2010
Table 56: EMERGING MARKETS FOR ENZYME INHIBITORS, THROUGH 2016
Table 57: EMERGING MARKETS FOR PROTON PUMP INHIBITORS, THROUGH 2016
Table 58: EMERGING MARKETS FOR PROTEASE INHIBITORS, THROUGH 2016
Table 59: EMERGING MARKETS FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH
2016
Table 60: EMERGING MARKETS FOR KINASE INHIBITORS, THROUGH 2016
Table 61: EMERGING MARKETS FOR STATINS, THROUGH 2016
Table 62: EMERGING MARKETS FOR AROMATASE INHIBITORS, THROUGH 2016
Table 63: EMERGING MARKETS FOR PDE5 INHIBITORS, THROUGH 2016
Table 64: EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, THROUGH 2016
Table 65: EMERGING MARKETS FOR ACE INHIBITORS, THROUGH 2016
Figure 40: EMERGING MARKETS SHARES OF PROTEASE INHIBITORS MANUFACTURERS,
2010
Figure 41: EMERGING MARKET SHARES OF KINASE INHIBITORS MANUACTURERS, 2010
Figure 42: EMERGING MARKETS SHARES OF STATINS MANUFACTURERS, 2010
Figure 43: EMERGING MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS,
2010
Figure 44: EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE MANUFACTURERS,
2010
Figure 45: EMERGING MARKET SHARES OF PED5 MANUFACTURERS, 2010
Figure 46: EMERGING MARKET SHARES OF NEURAMINIDASE MANUFACTURERS, 2010
Figure 47: EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010
Figure 48: EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC
CATEGORIES/DISEASE SECTORS
Figure 49: EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR
DISEASES, 2009-2016
Figure 50: EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL
DISEASES, 2009-2016
Figure 51: EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016
Figure 52: EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016
Figure 53: EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS,
2009-2016
Figure 54: EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,
2009-2016
Figure 55: EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES,
2009-2016
Figure 56: NUMBER OF PATENTS BY YEAR, 2008-2012
Figure 57: NUMBER OF PATENTS BY YEAR, 2008-2012
Figure 58: PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008 - 2012
Figure 59: TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS,
2008 - 2012
Figure 60: PATENT SHARES BY COUNTRY FOR ENZYME INHIBITORS, 2008 - 2012
Figure 61: PATENTS BY ASSIGNEE FOR INDUSTRIAL ENZYMES, 2008 - 2012
Global Markets for Enzyme Inhibitors -- Focus on Emerging Markets published by BCC Research in June 22, 2012. This report consists of 169 Pages and the price starts from US $ 4400.
